Intellia Therapeutics (NTLA) Current Deferred Revenue (2015 - 2026)

Intellia Therapeutics (NTLA) has reported Current Deferred Revenue for 12 consecutive years, with $630000.0 the latest figure, recorded in Q1 2026.

• In Q1 2026, Current Deferred Revenue fell 98.14% year-over-year to $630000.0; the TTM figure through Mar 2026 stood at $630000.0 (down 98.14% YoY), while the FY2025 annual figure was $7.3 million, down 81.27% from the prior year.
• Current Deferred Revenue retreated to $630000.0 in Q1 2026 per NTLA's latest filing, from $7.3 million in the prior quarter.
• Across five years, Current Deferred Revenue topped out at $113.2 million in Q1 2022 and bottomed at $630000.0 in Q1 2026.
• Historically, Current Deferred Revenue has averaged $47.7 million across 5 years, with a median of $44.8 million in 2024.
• Annual changes were most pronounced in 2024 — Current Deferred Revenue jumped 71.73% — and 2026, when it sank 98.14%.
• Intellia Therapeutics' Current Deferred Revenue stood at $63.8 million in 2022, then decreased by 4.36% to $61.0 million in 2023, then plunged by 36.19% to $38.9 million in 2024, then tumbled by 81.27% to $7.3 million in 2025, then sank by 91.36% to $630000.0 in 2026.
• Business Quant data shows NTLA's Current Deferred Revenue at $630000.0 in Q1 2026, $7.3 million in Q4 2025, and $24.8 million in Q3 2025.